{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:40:06Z","timestamp":1790066406723,"version":"4.0.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2021R1A6A1A03044296"],"award-info":[{"award-number":["2021R1A6A1A03044296"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Food and Drug Safety of South Korea","award":["22183MFDS366"],"award-info":[{"award-number":["22183MFDS366"]}]},{"DOI":"10.13039\/501100002460","name":"Chung-Ang University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002460","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s15010-026-02745-7","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T14:19:24Z","timestamp":1774361964000},"page":"1299-1318","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of vancomycin versus 13 alternatives in MRSA-confirmed skin and soft tissue infections: a meta-analysis of 39 randomized controlled trials"],"prefix":"10.1007","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6507-915X","authenticated-orcid":false,"given":"Sujata","family":"Purja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9467-1313","authenticated-orcid":false,"given":"Yomna","family":"Elghanam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3525-8805","authenticated-orcid":false,"given":"Eunyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"issue":"4","key":"2745_CR1","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1086\/651094","volume":"31","author":"GA Filice","year":"2010","unstructured":"Filice GA, Nyman JA, Lexau C, Lees CH, Bockstedt LA, Como-Sabetti K, et al. Excess costs and utilization associated with methicillin resistance for patients with Staphylococcus aureus infection. Infect Control Hosp Epidemiol. 2010;31(4):365\u201373. https:\/\/doi.org\/10.1086\/651094.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"4","key":"2745_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41579-018-0147-4","volume":"17","author":"NA Turner","year":"2019","unstructured":"Turner NA, Sharma-Kuinkel BK, Maskarinec SA, Eichenberger EM, Shah PP, Carugati M, et al. Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research. Nat Rev Microbiol. 2019;17(4):203\u201318. https:\/\/doi.org\/10.1038\/s41579-018-0147-4.","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"2745_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlaa114","volume":"3","author":"NM Brown","year":"2021","unstructured":"Brown NM, Goodman AL, Horner C, Jenkins A, Brown EM. Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK. JAC Antimicrob Resist. 2021;3(1):dlaa114. https:\/\/doi.org\/10.1093\/jacamr\/dlaa114.","journal-title":"JAC Antimicrob Resist"},{"issue":"3","key":"2745_CR4","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1093\/cid\/ciq146","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18-55. https:\/\/doi.org\/10.1093\/cid\/ciq146.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2745_CR5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.cmi.2017.06.017","volume":"24","author":"R Diaz","year":"2018","unstructured":"Diaz R, Afreixo V, Ramalheira E, Rodrigues C, Gago B. Evaluation of vancomycin MIC creep in methicillin-resistant Staphylococcus aureus infections-a systematic review and meta-analysis. Clin Microbiol Infect. 2018;24(2):97\u2013104. https:\/\/doi.org\/10.1016\/j.cmi.2017.06.017.","journal-title":"Clin Microbiol Infect"},{"key":"2745_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2024.08.021","author":"V Galfo","year":"2024","unstructured":"Galfo V, Tiseo G, Riccardi N, Falcone M. Therapeutic drug monitoring of antibiotics for methicillin-resistant Staphylococcus aureus infections: an updated narrative review for clinicians. Clin Microbiol Infect. 2024. https:\/\/doi.org\/10.1016\/j.cmi.2024.08.021.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"2745_CR7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.77949","volume":"17","author":"IM Dighriri","year":"2025","unstructured":"Dighriri IM, Alanazi S, AlMutairi K, Alhusayni SJ, Balharith FM, Aljuwaie RA, et al. Efficacy and Safety of Vancomycin, Linezolid, and Ceftaroline in the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA): A Systematic Review and Meta-Analysis. Cureus. 2025;17(1):e77949. https:\/\/doi.org\/10.7759\/cureus.77949.","journal-title":"Cureus"},{"key":"2745_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2024.107109","volume":"146","author":"G Ju","year":"2024","unstructured":"Ju G, Zhang Y, Ye C, Liu Q, Sun H, Zhang Z, et al. Comparative effectiveness and safety of six antibiotics in treating MRSA infections: A network meta-analysis. Int J Infect Dis. 2024;146:107109. https:\/\/doi.org\/10.1016\/j.ijid.2024.107109.","journal-title":"Int J Infect Dis"},{"key":"2745_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics13090866","author":"Q Liu","year":"2024","unstructured":"Liu Q, He D, Wang L, Wu Y, Liu X, Yang Y, et al. Efficacy and safety of antibiotics in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections: a systematic review and network meta-analysis. Antibiotics Basel. 2024. https:\/\/doi.org\/10.3390\/antibiotics13090866.","journal-title":"Antibiotics Basel"},{"issue":"5","key":"2745_CR10","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1128\/aac.02106-12","volume":"57","author":"WT Prince","year":"2013","unstructured":"Prince WT, Ivezic-Schoenfeld Z, Lell C, Tack KJ, Novak R, Obermayr F, et al. Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2013;57(5):2087\u201394. https:\/\/doi.org\/10.1128\/aac.02106-12.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"2745_CR11","doi-asserted-by":"publisher","first-page":"5476","DOI":"10.1128\/aac.00712-12","volume":"56","author":"ME Stryjewski","year":"2012","unstructured":"Stryjewski ME, Potgieter PD, Li YP, Barriere SL, Churukian A, Kingsley J, et al. TD-1792 versus vancomycin for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother. 2012;56(11):5476\u201383. https:\/\/doi.org\/10.1128\/aac.00712-12.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 4","key":"2745_CR12","doi-asserted-by":"publisher","first-page":"iv41","DOI":"10.1093\/jac\/dkq254","volume":"65","author":"GR Corey","year":"2010","unstructured":"Corey GR, Wilcox MH, Talbot GH, Thye D, Friedland D, Baculik T. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65(Suppl 4):iv41-51. https:\/\/doi.org\/10.1093\/jac\/dkq254.","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"2745_CR13","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.1093\/jac\/dkw333","volume":"71","author":"M Dryden","year":"2016","unstructured":"Dryden M, Zhang Y, Wilson D, Iaconis JP, Gonzalez J. A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities. J Antimicrob Chemother. 2016;71(12):3575\u201384. https:\/\/doi.org\/10.1093\/jac\/dkw333.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"2745_CR14","doi-asserted-by":"publisher","first-page":"3612","DOI":"10.1128\/aac.00590-07","volume":"51","author":"GH Talbot","year":"2007","unstructured":"Talbot GH, Thye D, Das A, Ge Y. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother. 2007;51(10):3612\u20136. https:\/\/doi.org\/10.1128\/aac.00590-07.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 4","key":"2745_CR15","doi-asserted-by":"publisher","first-page":"iv53","DOI":"10.1093\/jac\/dkq255","volume":"65","author":"MH Wilcox","year":"2010","unstructured":"Wilcox MH, Corey GR, Talbot GH, Thye D, Friedland D, Baculik T. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65(Suppl 4):iv53\u201365. https:\/\/doi.org\/10.1093\/jac\/dkq255.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"2745_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1128\/aac.00551-07","volume":"52","author":"GJ Noel","year":"2008","unstructured":"Noel GJ, Strauss RS, Amsler K, Heep M, Pypstra R, Solomkin JS. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother. 2008;52(1):37\u201344. https:\/\/doi.org\/10.1128\/aac.00551-07.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2745_CR17","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1086\/526527","volume":"46","author":"GJ Noel","year":"2008","unstructured":"Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis. 2008;46(5):647\u201355. https:\/\/doi.org\/10.1086\/526527.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"2745_CR18","doi-asserted-by":"publisher","first-page":"e1507","DOI":"10.1093\/cid\/ciaa974","volume":"73","author":"JS Overcash","year":"2021","unstructured":"Overcash JS, Kim C, Keech R, Gumenchuk I, Ninov B, Gonzalez-Rojas Y, et al. Ceftobiprole compared with vancomycin plus aztreonam in the treatment of acute bacterial skin and skin structure infections: results of a Phase 3, randomized, double-blind trial (TARGET). Clin Infect Dis. 2021;73(7):e1507\u201317. https:\/\/doi.org\/10.1093\/cid\/ciaa974.","journal-title":"Clin Infect Dis"},{"issue":"23","key":"2745_CR19","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","volume":"370","author":"HW Boucher","year":"2014","unstructured":"Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370(23):2169\u201379. https:\/\/doi.org\/10.1056\/NEJMoa1310480.","journal-title":"N Engl J Med"},{"issue":"3","key":"2745_CR20","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10156-012-0501-9","volume":"19","author":"N Aikawa","year":"2013","unstructured":"Aikawa N, Kusachi S, Mikamo H, Takesue Y, Watanabe S, Tanaka Y, et al. Efficacy and safety of intravenous daptomycin in Japanese patients with skin and soft tissue infections. J Infect Chemother. 2013;19(3):447\u201355. https:\/\/doi.org\/10.1007\/s10156-012-0501-9.","journal-title":"J Infect Chemother"},{"issue":"9","key":"2745_CR21","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1111\/j.1742-1241.2008.01854.x","volume":"62","author":"DE Katz","year":"2008","unstructured":"Katz DE, Lindfield KC, Steenbergen JN, Benziger DP, Blackerby KJ, Knapp AG, et al. A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria. Int J Clin Pract. 2008;62(9):1455\u201364. https:\/\/doi.org\/10.1111\/j.1742-1241.2008.01854.x.","journal-title":"Int J Clin Pract"},{"key":"2745_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-1261-9","volume":"15","author":"TL Kauf","year":"2015","unstructured":"Kauf TL, McKinnon P, Corey GR, Bedolla J, Riska PF, Sims M, et al. An open-label, pragmatic, randomized controlled clinical trial to evaluate the comparative effectiveness of daptomycin versus vancomycin for the treatment of complicated skin and skin structure infection. BMC Infect Dis. 2015;15:503. https:\/\/doi.org\/10.1186\/s12879-015-1261-9.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"2745_CR23","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/j.1742-1241.2008.01988.x","volume":"63","author":"PE Pertel","year":"2009","unstructured":"Pertel PE, Eisenstein BI, Link AS, Donfrid B, Biermann EJ, Bernardo P, et al. The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas. Int J Clin Pract. 2009;63(3):368\u201375. https:\/\/doi.org\/10.1111\/j.1742-1241.2008.01988.x.","journal-title":"Int J Clin Pract"},{"issue":"3","key":"2745_CR24","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1093\/jac\/dkv411","volume":"71","author":"J Kingsley","year":"2016","unstructured":"Kingsley J, Mehra P, Lawrence LE, Henry E, Duffy E, Cammarata SK, et al. A randomized, double-blind, Phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin. J Antimicrob Chemother. 2016;71(3):821\u20139. https:\/\/doi.org\/10.1093\/jac\/dkv411.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"2745_CR25","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/cid\/ciy165","volume":"67","author":"W O'Riordan","year":"2018","unstructured":"O\u2019Riordan W, McManus A, Teras J, Poromanski I, Cruz-Saldariagga M, Quintas M, et al. A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: a Phase 3, multinational, double-blind, randomized study. Clin Infect Dis. 2018;67(5):657\u201366. https:\/\/doi.org\/10.1093\/cid\/ciy165.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"2745_CR26","doi-asserted-by":"publisher","first-page":"3471","DOI":"10.1093\/jac\/dkx329","volume":"72","author":"J Pullman","year":"2017","unstructured":"Pullman J, Gardovskis J, Farley B, Sun E, Quintas M, Lawrence L, et al. Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: A Phase 3, double-blind, randomized study. J Antimicrob Chemother. 2017;72(12):3471\u201380. https:\/\/doi.org\/10.1093\/jac\/dkx329.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"2745_CR27","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1128\/aac.01383-08","volume":"53","author":"D Krievins","year":"2009","unstructured":"Krievins D, Brandt R, Hawser S, Hadvary P, Islam K. Multicenter, randomized study of the efficacy and safety of intravenous iclaprim in complicated skin and skin structure infections. Antimicrob Agents Chemother. 2009;53(7):2834\u201340. https:\/\/doi.org\/10.1128\/aac.01383-08.","journal-title":"Antimicrob Agents Chemother"},{"key":"2745_CR28","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02580-17","author":"TL Holland","year":"2018","unstructured":"Holland TL, O\u2019Riordan W, McManus A, Shin E, Borghei A, File TM Jr., et al. A Phase 3, randomized, double-blind, multicenter study to evaluate the safety and efficacy of intravenous Iclaprim versus Vancomycin for treatment of acute bacterial skin and skin structure infections suspected or confirmed to be due to Gram-Positive Pathogens (REVIVE-2 Study). Antimicrob Agents Chemother. 2018. https:\/\/doi.org\/10.1128\/aac.02580-17.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"2745_CR29","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1093\/cid\/cix987","volume":"66","author":"DB Huang","year":"2018","unstructured":"Huang DB, O\u2019Riordan W, Overcash JS, Heller B, Amin F, File TM, et al. A Phase 3, randomized, double-blind, multicenter study to evaluate the safety and efficacy of intravenous iclaprim vs vancomycin for the treatment of acute bacterial skin and skin structure infections suspected or confirmed to be due to Gram-Positive pathogens: REVIVE-1. Clin Infect Dis. 2018;66(8):1222\u20139. https:\/\/doi.org\/10.1093\/cid\/cix987.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2745_CR30","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.amjsurg.2009.08.045","volume":"199","author":"KM Itani","year":"2010","unstructured":"Itani KM, Dryden MS, Bhattacharyya H, Kunkel MJ, Baruch AM, Weigelt JA. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus. Am J Surg. 2010;199(6):804\u201316. https:\/\/doi.org\/10.1016\/j.amjsurg.2009.08.045.","journal-title":"Am J Surg"},{"issue":"6","key":"2745_CR31","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1093\/jac\/dkm369","volume":"60","author":"S Kohno","year":"2007","unstructured":"Kohno S, Yamaguchi K, Aikawa N, Sumiyama Y, Odagiri S, Aoki N, et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. J Antimicrob Chemother. 2007;60(6):1361\u20139. https:\/\/doi.org\/10.1093\/jac\/dkm369.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"2745_CR32","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.amjsurg.2005.01.011","volume":"189","author":"JN Sharpe","year":"2005","unstructured":"Sharpe JN, Shively EH, Polk HC Jr. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am J Surg. 2005;189(4):425\u20138. https:\/\/doi.org\/10.1016\/j.amjsurg.2005.01.011.","journal-title":"Am J Surg"},{"issue":"11","key":"2745_CR33","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1086\/340353","volume":"34","author":"DL Stevens","year":"2002","unstructured":"Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 2002;34(11):1481\u201390. https:\/\/doi.org\/10.1086\/340353.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2745_CR34","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1128\/aac.49.6.2260-2266.2005","volume":"49","author":"J Weigelt","year":"2005","unstructured":"Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2005;49(6):2260\u20136. https:\/\/doi.org\/10.1128\/aac.49.6.2260-2266.2005.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2745_CR35","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1086\/595686","volume":"48","author":"MH Wilcox","year":"2009","unstructured":"Wilcox MH, Tack KJ, Bouza E, Herr DL, Ruf BR, Ijzerman MM, et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: Noninferiority of linezolid in a phase 3 study. Clin Infect Dis. 2009;48(2):203\u201312. https:\/\/doi.org\/10.1086\/595686.","journal-title":"Clin Infect Dis"},{"issue":"23","key":"2745_CR36","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1056\/NEJMoa1310422","volume":"370","author":"GR Corey","year":"2014","unstructured":"Corey GR, Kabler H, Mehra P, Gupta S, Overcash JS, Porwal A, et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med. 2014;370(23):2180\u201390. https:\/\/doi.org\/10.1056\/NEJMoa1310422.","journal-title":"N Engl J Med"},{"issue":"2","key":"2745_CR37","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1093\/cid\/ciu778","volume":"60","author":"GR Corey","year":"2015","unstructured":"Corey GR, Good S, Jiang H, Moeck G, Wikler M, Green S, et al. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin Infect Dis. 2015;60(2):254\u201362. https:\/\/doi.org\/10.1093\/cid\/ciu778.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2745_CR38","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/jac\/44.2.263","volume":"44","author":"RL Nichols","year":"1999","unstructured":"Nichols RL, Graham DR, Barriere SL, Rodgers A, Wilson SE, Zervos M, et al. Treatment of hospitalized patients with complicated Gram-Positive skin and skin structure infections: two randomized, multicentre studies of quinupristin\/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group. J Antimicrob Chemother. 1999;44(2):263\u201373. https:\/\/doi.org\/10.1093\/jac\/44.2.263.","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"2745_CR39","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1086\/429914","volume":"40","author":"ME Stryjewski","year":"2005","unstructured":"Stryjewski ME, O\u2019Riordan WD, Lau WK, Pien FD, Dunbar LM, Vallee M, et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis. 2005;40(11):1601\u20137. https:\/\/doi.org\/10.1086\/429914.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2745_CR40","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1128\/aac.50.3.862-867.2006","volume":"50","author":"ME Stryjewski","year":"2006","unstructured":"Stryjewski ME, Chu VH, O\u2019Riordan WD, Warren BL, Dunbar LM, Young DM, et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother. 2006;50(3):862\u20137. https:\/\/doi.org\/10.1128\/aac.50.3.862-867.2006.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"2745_CR41","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1086\/587896","volume":"46","author":"ME Stryjewski","year":"2008","unstructured":"Stryjewski ME, Graham DR, Wilson SE, O\u2019Riordan W, Young D, Lentnek A, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis. 2008;46(11):1683\u201393. https:\/\/doi.org\/10.1086\/587896.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"2745_CR42","doi-asserted-by":"publisher","first-page":"4658","DOI":"10.1128\/aac.49.11.4658-4666.2005","volume":"49","author":"J Breedt","year":"2005","unstructured":"Breedt J, Teras J, Gardovskis J, Maritz FJ, Vaasna T, Ross DP, et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother. 2005;49(11):4658\u201366. https:\/\/doi.org\/10.1128\/aac.49.11.4658-4666.2005.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 5","key":"2745_CR43","doi-asserted-by":"publisher","first-page":"S341","DOI":"10.1086\/431675","volume":"41","author":"EJ Ellis-Grosse","year":"2005","unstructured":"Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis. 2005;41(Suppl 5):S341\u201353. https:\/\/doi.org\/10.1086\/431675.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"2745_CR44","doi-asserted-by":"publisher","first-page":"i17","DOI":"10.1093\/jac\/dkn250","volume":"62","author":"I Florescu","year":"2008","unstructured":"Florescu I, Beuran M, Dimov R, Razbadauskas A, Bochan M, Fichev G, et al. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant *Staphylococcus aureus* or vancomycin-resistant enterococci: a phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother. 2008;62(Suppl 1):i17-28. https:\/\/doi.org\/10.1093\/jac\/dkn250.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"2745_CR45","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.ijid.2005.05.003","volume":"9","author":"S Sacchidanand","year":"2005","unstructured":"Sacchidanand S, Penn RL, Embil JM, Campos ME, Curcio D, Ellis-Grosse E, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial. Int J Infect Dis. 2005;9(5):251\u201361. https:\/\/doi.org\/10.1016\/j.ijid.2005.05.003.","journal-title":"Int J Infect Dis"},{"issue":"4","key":"2745_CR46","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/jebm.12644","volume":"17","author":"S Purja","year":"2024","unstructured":"Purja S, Kim M, Elghanam Y, Shim HJ, Kim E. Efficacy and safety of vancomycin compared with those of alternative treatments for methicillin-resistant *Staphylococcus aureus* infections: an umbrella review. J Evid Based Med. 2024;17(4):729\u201339. https:\/\/doi.org\/10.1111\/jebm.12644.","journal-title":"J Evid Based Med"},{"issue":"2","key":"2745_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000033.pub3","volume":"2","author":"A Lundh","year":"2017","unstructured":"Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2017;2(2):Mr000033. https:\/\/doi.org\/10.1002\/14651858.MR000033.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"2745_CR48","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/annonc\/mdy305","volume":"29","author":"F Liang","year":"2018","unstructured":"Liang F, Zhu J, Mo M, Zhou CM, Jia HX, Xie L, et al. Role of industry funders in oncology RCTs published in high-impact journals and its association with trial conclusions and time to publication. Ann Oncol. 2018;29(10):2129\u201334. https:\/\/doi.org\/10.1093\/annonc\/mdy305.","journal-title":"Ann Oncol"},{"issue":"4","key":"2745_CR49","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1128\/aac.34.4.550","volume":"34","author":"DP Healy","year":"1990","unstructured":"Healy DP, Sahai JV, Fuller SH, Polk RE. Vancomycin-induced histamine release and \u201cred man syndrome\u201d: comparison of 1- and 2-hour infusions. Antimicrob Agents Chemother. 1990;34(4):550\u20134. https:\/\/doi.org\/10.1128\/aac.34.4.550.","journal-title":"Antimicrob Agents Chemother"},{"key":"2745_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.116077","volume":"266","author":"D Nawrot","year":"2024","unstructured":"Nawrot D, Ambro\u017ckiewicz-Mosler W, Dole\u017eal M, Bouz G. Antistaphylococcal discovery pipeline; where are we now? Eur J Med Chem. 2024;266:116077. https:\/\/doi.org\/10.1016\/j.ejmech.2023.116077.","journal-title":"Eur J Med Chem"},{"issue":"10","key":"2745_CR51","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.1128\/aac.00373-06","volume":"50","author":"CE Nord","year":"2006","unstructured":"Nord CE, Sillerstr\u00f6m E, Wahlund E. Effect of tigecycline on normal oropharyngeal and intestinal microflora. Antimicrob Agents Chemother. 2006;50(10):3375\u201380. https:\/\/doi.org\/10.1128\/aac.00373-06.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2745_CR52","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.clinthera.2007.06.014","volume":"29","author":"MN Jeffres","year":"2007","unstructured":"Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther. 2007;29(6):1107\u201315. https:\/\/doi.org\/10.1016\/j.clinthera.2007.06.014.","journal-title":"Clin Ther"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02745-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-026-02745-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02745-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:48:47Z","timestamp":1782920927000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-026-02745-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2745"],"URL":"https:\/\/doi.org\/10.1007\/s15010-026-02745-7","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"16 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable. This study is a systematic review and meta-analysis of previously published data and did not involve any direct interaction with human participants or access to individual-level patient data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable. No new data were collected from human participants for this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}